Supplementary Material for: Imatinib Treatment in Primary Acute Basophilic Leukemia with FIP1L1-PDGFRα Rearrangement: A Case Report

Acute Basophilic Leukemia (ABL) is a rare form of acute leukemia, defined by an elevated number of immature basophils in the peripheral blood. Clinically, it presents with skin infiltration, organ enlargement, osteolytic lesions, and elevated histamine levels and symptoms, with rapid progression and poor prognosis. Due to its rarity and the lack of specialized diagnostic tests, there is no consistent diagnostic standard. This report describes a rare case of acute basophilic leukemia that not only enhances our understanding of the clinical manifestations and pathological mechanisms of ABL, but also highlights the importance of precise diagnosis and individualized treatment. The detailed analysis of this case facilitated the identification of early symptoms of ABL, especially the relevance to the clinical manifestations of hyperhistaminemia. Meanwhile, the FIP1L1::PDGFRA fusion gene detection results strongly support the use of molecular diagnosis in ABL. In addition, the patient successfully achieved a complete response to treatment and was followed for a year and a half without relapse, thus offering valuable insights for treatment strategies in similar cases.

急性嗜碱性粒细胞白血病（Acute Basophilic Leukemia，ABL）是一种罕见的急性白血病类型，以对外周血中未成熟嗜碱性粒细胞数量升高为特征。临床上，该疾病表现为皮肤浸润、器官肿大、溶骨性病变，以及组胺水平升高与相关症状，病情进展迅速且预后不良。由于其发病率极低且缺乏专用诊断检测手段，目前尚无统一的诊断标准。本报告描述了一例罕见的急性嗜碱性粒细胞白血病病例，不仅加深了我们对ABL临床表现与病理机制的认知，同时凸显了精准诊断与个体化治疗的重要性。对该病例的详细分析有助于明确ABL的早期症状，尤其是其与高组胺血症临床表现的相关性。与此同时，FIP1L1::PDGFRA融合基因检测结果为ABL的分子诊断应用提供了有力支撑。此外，该患者经治疗后成功获得完全缓解，且经过一年半的随访未出现复发，可为同类病例的治疗策略提供宝贵参考。